COVID-19 vaccine effectiveness
(Randomized evidence)
Analyses are updated every Friday
Variants of concern
Treatment comparisons
Please choose a Treatment Comparison:
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04510207, ChiCTR2000034780 Sinopharm - China National Biotec Group Company Limited Al Kaabi N, JAMA, 2021 Full text Commentary Commentary |
Inactivated virus |
WIV04 HBO2 |
Placebo |
RCTPhase 3 | Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain | N=40411 |
Some concerns Details |
|
|
NCT04651790 Sinovac Research and Development Co., Ltd Bueno S, medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac |
Placebo |
RCTPhase 3 | Adult healthcare workers with no history of confirmed symptomatic SARS-CoV-2 infection who were in contact with possible or confirmed cases of COVID-19 in 8 sites in Chile. | N=434 |
Low Details |
|
|
NCT04412538 Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAMS). Che Y, Clin Infect Dis, 2020 Full text Commentary |
Inactivated virus |
KMS-1 100 EU D0/14 KMS-1 150 EU D0/14 KMS-1 100 EU D0/28 KMS-1 150 EU D0/28 |
Adjuvant D0/14 |
RCTPhase 2 | Healthy SARS-CoV-2 serology/DNA negative adults in two centres in China | N=750 |
Some concerns Details |
|
|
NCT04471519 ; CTRI/2 Bharat Biotech Ella R, Lancet Infect Dis, 2021 Full text Commentary ; Commentary |
Inactivated virus |
6mcg BBV152 + Algel-IMDG |
3mcg BBV152 + Algel-IMDG |
RCTPhase 2 | Healthy adults (<65 yo) and children (≥12 yo)volunteers, SARS-CoV-2 infection-free in 9 centres in India | N=380 |
Some concerns Details |
|
|
NCT04641481 Bharat Biotech Ella R, medRxiv, 2021 New Full text Commentary Commentary |
Inactivated virus |
BBV152 |
Placebo |
RCT3 | Adults with no history of SARS-CoV-2 infection who were healthy or had stable chronic medical conditions at 25 centers in India | N=25778 |
Some concerns Details |
|
|
NCT04471519 ; CTRI/2 Bharat Biotech Ella R, Lancet Infect Dis, 2021 Full text Commentary |
Inactivated virus |
BBV152 3mcg + Algel-IMDG BBV152 6mcg + Algel-IMDG BBV152 6mcg + Algel D0/1 |
Adjuvant D0/14 |
RCTPhase 1 | Healthy SARS-CoV-2 serology/PCR negative adults in 11 centres in India | N=375 |
Low Details |
|
|
NCT04551547 Sinovac Research and Development Co., Ltd Han B, SSRN, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac 1.5 mcg D0/28 Adjuvant D0/28 |
CoronaVac 3.0 mcg D0/28 |
RCTPhase 1/2 | Healthy children and adolescents aged 3-17 years with no history of SARS-CoV-2 infection in a single centre in China. | N=552 |
Low Details |
|
|
NCT04456595 Sinovac Research and Development Co., Ltd Palacios R, SSRN, 2021 PROFISCOV Full text Commentary |
Inactivated virus |
CoronaVac |
Placebo |
RCTPhase 3 | Healthcare professionals with or without previous COVID-19 infection caring for COVID-19 patients at 16 centers in Brazil. | N=12408 |
Some concerns Details |
|
|
NCT04756323, ChiCTR2000039462 Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Pan HX, Chin Med J, 2021 Full text Commentary |
Inactivated virus |
KCONVAC 5mcg D0/14 KCONVAC 5mcg D0/14 KCONVAC 5mcg D0/28 KCONVAC 5mcg D0/28 KCONVAC 5mcg D0/14 KCONVAC 10mcg D0/14 |
KCONVAC 10mcg D0/14 KCONVAC 5mcg D0/14 KCONVAC 10mcg D0/28 Placebo D0/28 Placebo D0/14 Placebo D0/14 |
RCTPhase 2 | Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China. | N=500 |
Low Details |
|
|
NCT04758273, ChiCTR2000038804 Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Pan HX, Chin Med J, 2021 Full text Commentary |
Inactivated virus |
5mcg KCONVAC |
10mcg KCONVAC |
RCTPhase 1 | Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China. | N=60 |
Low Details |
|
|
NCT04412538 The Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAM Pu J, Vaccine, 2021 Full text Commentary |
Inactivated virus |
KMS-1 100 EU D0/14 KMS-1 100 EU D0/28 |
Placebo D0/14 |
RCTPhase 1 | Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China | N=192 |
Some concerns Details |
|
|
NCT04582344 Sinovac Research and Development Co., Ltd Tanriover M, Lancet , 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac |
Adjuvant |
RCTPhase 3 | Healthy healthcare workers and adults aged 18–59 years with no history of COVID-19 from 24 centres in Turkey | N=10218 |
Some concerns Details |
|
|
NCT04383574 Sinovac Research and Development Co., Ltd Wu Z, Lancet Infect Dis, 2021 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac 1.5mcg D0/28 CoronaVac CoronaVac 6mcg D0/28 |
Adjuvant |
RCTPhase 1/2 | Healthy adults aged 60 years and older with no history of SARS-CoV-2 infection in a single centre in China | N=422 |
Low Details |
|
|
ChiCTR2000031809 Wuhan Institute of Biological Products Co Ltd./Sinopharm Xia S, JAMA, 2020 Full text Commentary |
Inactivated virus |
Inactivated 2.5mcg-3doses Inactivated 5mcg-3doses Inactivated 10mcg-3doses Inactivated 5mcg-D0/14 Inactivated 5mcg-D0/21 |
Adjuvant |
RCTPhase 1 | Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test | N=320 |
Low Details |
|
|
ChiCTR2000032459 Beijing Institute of Biological Products/Sinopharm Xia S, Lancet Infect Dis, 2020 Full text Commentary |
Inactivated virus |
BBIBP-CorV 8mcg once BBIBP-CorV 4mcg D0/14 BBIBP-CorV 4mcg D0/21 BBIBP-CorV 4mcg D0/28 |
Adjuvant |
RCTPhase 2 | Healthy SARS-CoV-2 serology negative adults 18-59 years old and ≥60 years old in a single centre in China | N=448 |
Some concerns Details |
|
|
NCT04352608 Sinovac Research and Development Co., Ltd Zhang Y, Lancet Infect Dis, 2020 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac CoronaVac 6 mcg D0/14 CoronaVac 3 mcg D0/28 CoronaVac 6 mcg D0/28 |
Adjuvant |
RCTPhase 2 | Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China | N=600 |
Some concerns Details |
|
|
NCT04352608 Sinovac Research and Development Co., Ltd Zhang Y, Lancet Infect Dis, 2020 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac 6 mcg D0/28 CoronaVac 3 mcg D0/28 CoronaVac 6 mcg D0/14 CoronaVac |
Adjuvant |
RCTPhase 1 | Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China | N=144 |
Some concerns Details |
|